HGSI

Pharma

GSK starts $2.6B HGSI bid; HGSI will respond in 10 business days

GlaxoSmithKline‘s (NYSE:GSK) forced Human Genome Sciences’ (NASDAQ:HGSI) hand and now the biotechnology company must make a decision about its future on a much faster timetable than it would have liked. GSK today formally commenced its offer to buy HGS at $13 per share, about $2.6 billion, and the British pharmaceuticals giant said shareholders should be […]

presented by
Pharma

GSK and HGSI test injectable version of lupus drug Benlysta

GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have started clinical trials on a different version of lupus drug Benlysta that would be easier to administer to patients. Benlysta is currently administered by intravenous infusion. The companies have started a phase 3 clinical trial to test a once-a-week injectable version of the drug. Studies […]

News

GSK’s Benlysta: The new face of a ‘blockbuster’ drug (with more to come)

The lupus drug Benlysta is a perfect example of the new blockbuster drug: expensive products targeting ever more specific segments of the patient population. And as GSK and other pharmaceutical companies continue working on biologics, expect more of this to come. Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GSK signed a development and commercialization agreement with Human Genome Sciences in which the two companies would share equally in the costs and net proceeds that come from it.